WO2025046540 - IMMUNE-RELATED GENE EXPRESSION SIGNATURES AND METHODS RELATING THERETO
National phase entry is expected:
Publication Number
WO/2025/046540
Publication Date
06.03.2025
International Application No.
PCT/IB2024/058472
International Filing Date
30.08.2024
Title **
[English]
IMMUNE-RELATED GENE EXPRESSION SIGNATURES AND METHODS RELATING THERETO
[French]
SIGNATURES D'EXPRESSION GÉNIQUE LIÉES À L'IMMUNITÉ ET PROCÉDÉS ASSOCIÉS
Applicants **
BEIGENE SWITZERLAND GMBH
Inventors
LIANG, Liang
MA, Xiaopeng
ZHANG, Yun
SHEN, Zhirong
Priority Data
PCT/CN2023/116516
01.09.2023
CN
PCT/CN2023/125271
18.10.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6155 | |
| EPO | Filing, Examination, Granting | 138851 | |
| Japan | Filing, Examination, Granting | 5022 | |
| South Korea | Filing, Examination, Granting | 9279 | |
| USA | Filing, Examination, Granting | 32590 |
Total:
191,897
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Among other things, the present disclosure provides methods for determining responsiveness to cancer treatments and methods of treating a subject having cancer comprising administering a cancer treatment, wherein the subject has been determined to be responsive to the cancer treatment. In some embodiments, a subject is determined to be responsive to a cancer treatment when a level of a gene expression signature is elevated. In some embodiments, a cancer treatment comprises a pharmaceutical composition comprising a PD-1 or PD-L1 inhibitor. In some embodiments, a cancer treatment comprises a pharmaceutical composition comprising a PD-1 or PD-L1 inhibitor and one or more pharmaceutical compositions comprising one or more therapeutic agents.[French]
La présente divulgation concerne entre autres des procédés de détermination de la sensibilité à des traitements anticancéreux et des méthodes de traitement d'un sujet atteint d'un cancer comprenant l'administration d'un traitement anticancéreux, le sujet ayant été déterminé comme étant sensible au traitement anticancéreux. Dans certains modes de réalisation, un sujet est déterminé comme étant sensible à un traitement anticancéreux lorsqu'un niveau d'une signature d'expression génique est élevé. Dans certains modes de réalisation, un traitement anticancéreux comprend une composition pharmaceutique comprenant un inhibiteur de PD-1 ou de PD-L1. Dans certains modes de réalisation, un traitement anticancéreux comprend une composition pharmaceutique comprenant un inhibiteur de PD-1 ou de PD-L1 et une ou plusieurs compositions pharmaceutiques comprenant un ou plusieurs agents thérapeutiques.